US PTAB Patent Cases
8,722 decisions indexed
Page 94 of 291 · 8,722 total
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck has filed a post‑grant review petition challenging Halozyme’s PH20 enzyme patent, asserting lack of written description and enablement. The reply argues the claims cover an unmanageable genus of mutants and cites case law to support unpatentability.
ZEPP HEALTH CORPORATION v.Worcester Polytechnic Institute
Zepp Health and Worcester Polytechnic Institute have entered a settlement that resolves all disputes over U.S. Patent 9,713,428. The parties filed a joint motion to terminate the inter partes review, which is pending before the Board.
ZEPP HEALTH CORPORATION v.Worcester Polytechnic Institute
Court decision.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck has filed a Post‑Grant Review petition challenging Halozyme’s U.S. Patent No. 12,054,758 covering engineered PH20 hyaluronidase proteins, arguing lack of written description, enablement, and obviousness.
Linkplay Technology Inc. et al. v.Sonos, Inc.
Linkplay Technology has filed an IPR petition seeking cancellation of all 20 claims of Sonos’s ’357 patent, alleging anticipation and obviousness over Richenstein, Chatterton, the MOST‑2.0 spec, and RFC1889. The petition argues that discretionary denial does not apply and requests institution of the review.
ZEPP HEALTH CORPORATION v.Worcester Polytechnic Institute
Zepp Health petitions the PTAB to institute an IPR against Worcester Poly's 9,713,428 patent covering wearable physiological monitoring, arguing the claims are obvious over multiple prior‑art references.
Shenzhen Root Technology Co., Ltd. et al. v.Willow Innovations, Inc. et al.
Court decision.
Axon Enterprise, Inc. et al. v.Airspace Systems, Inc.
Axon and Dedrone have filed an IPR petition challenging claim 21 of Airspace Systems’ low‑altitude aircraft identification patent, arguing obviousness over several UAV‑identification references and lack of proper priority. The petition seeks institution and cancellation of the claim.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully petitioned for institution in a PGR proceeding against Halozyme, Inc., challenging the '758 patent on grounds of enablement and obviousness. The Board adopted a broad claim construction for 'modified PH20 polypeptide,' which significantly broadened the scope of the challenged claims.
Shenzhen Root Technology Co., Ltd. et al. v.Willow Innovations, Inc. et al.
Shenzhen Root Technology Co., Ltd. successfully petitioned the PTAB to institute an IPR against Willow Blossom Holdco Limited's breast pump patent (11813381). The Board found a reasonable likelihood of unpatentability based on multiple grounds of obviousness under 35 U.S.C. § 103, citing combinations of prior art references like Chang and Fang.
Axon Enterprise, Inc. et al. v.Airspace Systems, Inc.
Axon and Dedrone successfully instituted an IPR against Airspace Systems regarding claim 21 of patent 10713959. The Board found a reasonable likelihood of unpatentability under 35 U.S.C. § 103 over the prior art reference Beard. This decision allows the challenge to proceed to trial, focusing on obviousness in low-altitude aircraft identification systems.
United Services Automobile Association v.Auto Telematics Ltd.
The USPTO denied USAA's request for Director Review of the institution decision in IPR2025-00812, leaving the institution of the auto‑telematics patent intact.
United Services Automobile Association v.Auto Telematics Ltd.
USAA defends the institution of an IPR against Auto Telematics, arguing the patent owner waived procedural arguments and that the ’728 vehicle‑data‑logging patent is obvious over multiple prior‑art references.
Valneva Austria GMBH v.Takeda Vaccines, Inc.
Valneva Austria and Takeda Vaccines jointly moved to terminate an IPR covering 67 vaccine‑related claims. The Board granted the motion, dismissing the petition without a merits decision.
United Services Automobile Association v.Auto Telematics Ltd.
Auto Telematics Ltd. has filed a Request for Director Review challenging the PTAB’s institution of an IPR against its vehicle‑telematics patent, arguing the Board misinterpreted claim language and ignored discretionary denial grounds.
Valneva Austria GMBH v.Takeda Vaccines, Inc.
Valneva has filed an IPR petition challenging all 67 claims of Takeda’s Zika vaccine patent, asserting anticipation and obviousness over multiple prior‑art references. The petitioner argues the examiner erred and that no discretionary bars apply, seeking cancellation of the entire patent.
Microsoft Corporation v.TS-Optics Corporation
Microsoft has filed an IPR petition challenging TS‑Optics’ U.S. Patent 7,266,055 covering optical pickup actuators. The petition asserts that all asserted claims are obvious over a suite of prior‑art references, including Choi, Ogata, Ikeda, Kamata, Santo, Kabasawa, Miura, and Sugiyama. Microsoft seeks institution of the IPR and cancellation of the claims.
United Services Automobile Association v.Auto Telematics Ltd.
USAA petitions the PTAB to invalidate Auto Telematics’ vehicle‑behavior logging patent, asserting that all 28 claims are obvious over a combination of existing telematics and accident‑detection references.
United Services Automobile Association v.Auto Telematics Ltd.
USAA successfully petitioned to institute IPR proceedings against Auto Telematics Ltd.'s patent covering driver behavior monitoring and accident detection technology. The Board found the claims were reasonably likely to be obvious over combinations of prior art references, moving the case toward trial.
Valneva Austria GMBH v.Takeda Vaccines, Inc.
Valneva Austria GMBH successfully convinced the PTAB to institute IPR proceedings against Takeda Vaccines regarding a vaccine patent. The Board found a reasonable likelihood that several claims are unpatentable over combinations of prior art, specifically citing evidence related to fetal protection and antibody transfer.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck’s petition reply contends that Halozyme’s hyaluronidase enzyme patent fails the written‑description and enablement requirements of 35 U.S.C. §112(a). The company argues the disclosed genus is too broad and impossible to enable without undue experimentation.
Henri Daussi, LLC v.ECNA, LLC et al.
The PTAB denied Henri Daussi, LLC's motion to withdraw its IPR petition against ECNA, LLC's patent 9,398,791, while allowing the parties to file a joint motion to terminate the proceeding after settling.
Henri Daussi, LLC v.ECNA, LLC et al.
Henri Daussi, LLC filed an unopposed motion to withdraw its IPR petition after reaching a settlement with patent owner ECNA, LLC. The Board has not yet issued an institution decision, and the parties seek termination of the proceeding.
Intel Corporation v.Advanced Cluster Systems, Inc.
Intel seeks rehearing after the PTAB Director denied institution of IPR2025‑00794, arguing that a recent $8.9 billion U.S. government investment makes its Xeon chips a national‑security priority and that the denial misapprehended this.
Intel Corporation v.Advanced Cluster Systems, Inc.
NVIDIA and Advanced Cluster Systems settled their dispute over a GPU clustering patent and jointly moved to terminate the inter partes review, leading the Board to end the proceeding.
Intel Corporation v.Advanced Cluster Systems, Inc.
Intel filed a request for rehearing after the PTAB Director denied institution of IPR2025‑00795, arguing that a recent $8.9 billion U.S. government investment makes its Xeon processors vital to national security. The petition contends the Director misapprehended the briefing and seeks referral to a merits panel.
Intel Corporation v.Advanced Cluster Systems, Inc.
Intel and Advanced Cluster Systems settled their dispute, filing a joint motion that led the PTAB to terminate the inter partes review of patent 10333768.
GE Healthcare Ltd. et al. v.The Johns Hopkins University et al.
GE Healthcare and Johns Hopkins University jointly moved to terminate IPR2025-00808 concerning patent 11,938,201. The Board granted the motion, ending the proceeding without prejudice and allowing future filing.
Henri Daussi, LLC v.ECNA, LLC et al.
The PTAB granted the parties’ joint request to keep their settlement agreement confidential after the IPR was terminated by mutual agreement.
Henri Daussi, LLC v.ECNA, LLC et al.
Henri Daussi, LLC and ECNA, LLC settled their dispute over U.S. Patent 9,398,791 B1 and jointly moved to terminate the inter partes review before the Board instituted the trial. The Board granted the motion, dismissing the petition.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.